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Purpose or Objective: The intent of this pooled analysis as 
part of the German Society for Radiation Oncology (DEGRO) 
stereotactic body radiotherapy (SBRT) initiative was to 
analyse the pattern of care of SBRT for liver metastases in 
Germany and to derive factors influencing local control and 
overall survival in a large patient cohort. 
 
Material and Methods: From 17 German and Swiss 
radiotherapy centers, data on all patients treated for liver 
metastases with SBRT since its introduction in 1997 was 
collected and entered into a centralised database as an 
effort of the SBRT task group of the DEGRO. In addition to 
patient and tumor characteristics, data on immobilization, 
image guidance and motion management as well as dose 
prescription and fractionation was gathered. Besides dose 
response and survival statistics, time trends of the 
aforementioned variables were investigated. 
 
Results: In total, 442 patients with 586 liver metastases 
(median 1 lesion/patient; range 1-4) have been collected 
from 1997 until 2014. Predominant histologies were 
colorectal cancer (n=213), lung cancer (n=26) and breast 
cancer (n=57). All centers employed a SBRT-specific setup 
(including abdominal compression in 41%). Initially, 
stereotactic coordinates and CT simulation was used for 
treatment set-up (55%), but eventually replaced by CBCT 
guidance (28%) or more recently robotic tracking (17%). High 
variance in fraction (fx) number (median 1 fx; range 1-13) 
and dose per fraction (median: 18.5 Gy; range 3-37.5 Gy) was 
observed, although median BED remained consistently high 
after an initial learning curve. Median follow-up time was 13 
months; median overall survival after SBRT was 24 months. 1 
and 2 year local control rate of treated lesions was 77% and 
64%; local control increased to 83% and 70%, respectively, if 
maximum isocenter biological equivalent dose (BED) was 
greater than 120 Gy EQD2Gy versus below that dose. 
 
Conclusion: After a learning curve with regards to total 
cumulative doses, consistent biologically effective doses 
were employed, although with a significant variation in 
number of fraction, single fraction dose and prescription 
isodose. A clear dose response was observed with high local 
control after 1 and 2 years with higher BED. Nevertheless, 
local control is still inferior compared to lung metastases 
with a similar distribution of histologies. Therefore, further 
analysis needs to investigate the influence of image guidance 
and motion management as well as radiation sensitivity on 
local tumor control. 
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Purpose or Objective: To define maximum tolerated dose 
(MTD) of stereotactic treatment (SBRT) performed in 
different clinical settings. 
 
Material and Methods: This analysis was based on a dose-
escalation (Phase I) trial. Patients were enrolled in seven 
different arms depending on treatment site and previous 
treatment: 1) intraparenchymal lung tumors; 2) lung tumors 
near to chest wall or to mediastinum; 3) extra pulmonary 
tumors; 4) re-irradiation after radiotherapy (< 60 Gy); 5) re-
irradiation after radiotherapy (> 60 Gy) or re-irradiation of 
pelvic and pancreatic tumors; 6) boost after a dose < 50Gy; 
7) boost after a dose ≥ 50Gy. SBRT was delivered in 5  
fractions. The dose was prescribed at isocenter with a 3D 
static technique using 4-5 non-coplanar beams or with VMAT 
technique. PTV was defined as the GTV + 5-15 mm. 
Considering study arms, the first group of patients received 
20 Gy, while other cohorts of patients received doses up to 
50 Gy. Grade 3 acute and late toxicities were considered as 
dose limiting toxicity (DLT). If 2/6 or 4/12 DLT were recorded 
in one cohort, that dose was considered as MTD. 
 
 
 
Results: 213 patients were enrolled (M/F: 125/88), median 
age was 69 years (35-90) and 281 lesions were treated (102 
primary tumors or local recurrences, 96 nodal and 83 distant 
metastases); they were mainly lung cancer (31%), 
gynaecologic cancer (24%), gastrointestinal neoplasms (22%), 
